These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9237782)

  • 21. Increased erythrocyte aldose reductase activity in type 1 diabetic patients.
    Hamada Y; Kito R; Raskin P
    Diabet Med; 1991 Apr; 8(3):226-31. PubMed ID: 1828737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proliferative diabetic retinopathy is related to cardiovascular autonomic neuropathy in non-insulin-dependent diabetes mellitus.
    Schmid H; Schaan B; Cecconello F; Maestri T; Neumann C
    Diabetes Res Clin Pract; 1995 Sep; 29(3):163-8. PubMed ID: 8591708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese Type 2 diabetic (T2DM) patients.
    Shimizu H; Ohtani KI; Tsuchiya T; Sato N; Tanaka Y; Takahashi H; Uehara Y; Inukai T; Mori M
    Diabetes Nutr Metab; 2000 Apr; 13(2):75-9. PubMed ID: 10898124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
    Song HP; Han XY; He Y; Kang TB; Wu HW
    Chin Med J (Engl); 1991 Oct; 104(10):818-24. PubMed ID: 1661222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of erythrocyte sorbitol-blood glucose ratios in type II diabetes mellitus.
    Aida K; Tawata M; Shindo H; Onaya T
    Diabetes Care; 1990 May; 13(5):461-7. PubMed ID: 2351023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of erythrocyte aldose reductase in man in response to glycaemic challenge.
    Lyons PA; Gould S; Wise PH; Palmer TN
    Diabetes Res Clin Pract; 1991 Oct; 14(1):9-13. PubMed ID: 1748066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.
    Cunningham JJ; Mearkle PL; Brown RG
    J Am Coll Nutr; 1994 Aug; 13(4):344-50. PubMed ID: 7963139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM.
    Nagi DK; Pettitt DJ; Bennett PH; Klein R; Knowler WC
    Diabet Med; 1997 Jun; 14(6):449-56. PubMed ID: 9212309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
    Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus.
    Makiishi T; Araki S; Koya D; Maeda S; Kashiwagi A; Haneda M
    Am J Kidney Dis; 2003 Nov; 42(5):943-51. PubMed ID: 14582038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes?
    Shehab D; Al-Jarallah K; Mojiminiyi OA; Al Mohamedy H; Abdella NA
    Diabet Med; 2012 Jan; 29(1):43-9. PubMed ID: 22050401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients.
    Teliti M; Cogni G; Sacchi L; Dagliati A; Marini S; Tibollo V; De Cata P; Bellazzi R; Chiovato L
    Diab Vasc Dis Res; 2018 Sep; 15(5):424-432. PubMed ID: 29911415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial cell density in cataractous lenses of patients with diabetes: association with erythrocyte aldose reductase.
    Kumamoto Y; Takamura Y; Kubo E; Tsuzuki S; Akagi Y
    Exp Eye Res; 2007 Sep; 85(3):393-9. PubMed ID: 17655844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relations between diabetic retinopathy and cardiovascular neuropathy--a cross-sectional study in IDDM and NIDDM patients.
    Zander E; Heinke P; Herfurth S; Reindel J; Ostermann FE; Kerner W
    Exp Clin Endocrinol Diabetes; 1997; 105(6):319-26. PubMed ID: 9439926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between erythrocyte aldose reductase activity and the width of skeletal-muscle capillary basement membrane in insulin-dependent diabetes mellitus.
    Hamada Y; Hammon K; Raskin P
    J Diabetes Complications; 1992; 6(4):242-6. PubMed ID: 1482782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.
    Stavniichuk R; Shevalye H; Hirooka H; Nadler JL; Obrosova IG
    Biochem Pharmacol; 2012 Apr; 83(7):932-40. PubMed ID: 22285226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.
    Prnova MS; Kovacikova L; Svik K; Bezek S; Elmazoğlu Z; Karasu C; Stefek M
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):651-661. PubMed ID: 31802170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
    Umeda F; Noda K; Hashimoto T; Yamashita T; Nawata H
    Diabetes Res; 1989 Nov; 12(3):125-9. PubMed ID: 2561396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.